Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 25Leukemia 13Neuroblastoma 12Myelodysplastic Syndromes 12Multiple Myeloma 12Recurrence 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Sarcoma 7Medulloblastoma 7Astrocytoma 7Lymphoma, Non-Hodgkin 6Wilms Tumor 5Osteosarcoma 5Central Nervous System Neoplasms 5Brain Neoplasms 5Sarcoma, Ewing 4Rhabdoid Tumor 4Retinoblastoma 4Optic Nerve Glioma 4Neoplasms 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4Hodgkin Disease 4Hematologic Neoplasms 4Burkitt Lymphoma 4Testicular Neoplasms 3

Interventions

Dexamethasone 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1filanesib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Steroids 1Specimen Handling 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Lenalidomide 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Plasmacytoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡